Roquefort Therapeutics PLC Non-Executive Director Appointment (6627I)
20 April 2022 - 4:11PM
UK Regulatory
TIDMROQ
RNS Number : 6627I
Roquefort Therapeutics PLC
20 April 2022
20 April 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Non-Executive Director Appointment
Significant Clinical Trial Expertise
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech
company focused on early-stage opportunities in the biotechnology
sector, is pleased to announce the appointment of Dr Simon Sinclair
as a Non-Executive Director with immediate effect. Dr Sinclair is a
commercial physician scientist leader with 20 years' pharma,
medtech and consumer healthcare industry experience in
translational medicine, clinical development, medical affairs,
evidence-based market access, medical safety, vigilance and
real-world evidence in both executive and non-executive roles.
During his career, Dr Sinclair has held senior roles at Johnson
and Johnson and Merck & Co. At Johnson and Johnson, Dr Sinclair
held the role of VP Medical Affairs (CMO) EMEA where he created an
integrated Medical Affairs function for Johnson and Johnson Medical
Devices across EMEA, a $6bn segment of the business. Prior to that
he served as International Clinical Director and WW VP Medical
Affairs where he set up and led the Medical Affairs function
globally for DePuy Synthes (part of Johnson and Johnson) Joint
Reconstruction. He was also responsible for DePuy Orthopaedics'
non-US Clinical research strategy and execution. He guided new
product development, registration and post-market strategies from a
Clinical Evidence perspective. He also oversaw the company's global
Medical Safety product surveillance.
At Merck & Co, Dr Sinclair was Head of Global Trial
Optimization, where he revolutionised Merck's approach to the
conduct of its clinical trials globally. He developed and installed
a new strategy and process to oversee the execution of clinical
development programmes from proof of concept onwards. This included
ensuring the design of clinical studies was optimised for
execution; the definition of geographical and temporal models for
clinical programs and individual studies; the development and
implementation of impactful patient recruitment and retention
strategies; and risk assessment, mitigation and control during
study conduct. Dr Sinclair also served as Senior Director Clinical
Research Operations, USA at Merck, where he led clinical research
operations in several therapeutic areas, including neuroscience,
ophthalmology, respiratory, gastro-intestinal, endocrinology,
clinical pharmacology and experimental medicine.
Dr Sinclair is currently Chief Safety Officer of Reckitt
Benckiser Group plc ("Reckitt") where he is responsible for guiding
and evaluating the safety of all its products to protect its
consumers, and for building and maintaining consumers' trust in
Reckitt. Simon also holds the role of Executive Director and Chair
at the Reckitt Global Hygeine Institute, where using a $25m seed
fund from Reckitt, he created and established the new non-profit
organisation. Additionally, Dr Sinclair is a Non-Executive Board
member of Ondine Biomedical Inc., an AIM listed life sciences
company focused on photodisinfection-based therapies to prevent and
treat a broad spectrum of infections, including those caused by
drug-resistant pathogens. He is also Non-Executive Director at
Renovos Biologics Limited, an orthopaedic biotech company.
Dr Sinclair is a renowned scientist with a PhD in neural
transplantation from Cambridge University, medical degree and
numerous publications in scientific journals throughout his
career.
Stephen West, Roquefort Therapeutics Executive Chairman,
commented:
"We are delighted to welcome Simon Sinclair to the Board of
Roquefort Therapeutics, where his directly relevant expertise in
driving clinical programmes will be of signficiant value to the
Company. Simon has extensive experience in briging novel, safe and
meaningful technologies and therapies to global healthcare systems
and patients worldwide and I look forward to working him to drive
our pre-clinical programmes forward to clinical trials and
beyond."
Commenting on his appointment, Roquefort Therapeutics NED Simon
Sinclair said:
"I am excited to join the Board of Roquefort Therapeutics. The
science behind the Company's studies and therapeutic potential of
Midkine really stood out to me and underpinned my decision to join
the Board. I look forward to working with the team on developing
its preclinical drug programme in cancer and exploring further
health benefits that inhibiting Midkine could potentially bring to
patients."
-Ends-
Enquiries:
Roquefort Therapeutics plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
+44 (0)20 7466
Optiva Securities Limited (Broker) 5000
+44 (0)20 3411
Christian Dennis 1881
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech
company developing products through the pre-clinical phase prior to
partnering or selling to big pharma. The Company is focused on
developing first in class Midkine inhibiting RNA therapeutics drugs
for the treatment of cancer, chronic inflammation, autoimmune
disorder and COVID-19. Recent progress within mRNA therapeutics has
led to a reduction in drug development timelines and costs,
increasing the chance of early value creation.
Through extensive research resulting in validation through
publication in over 1,000 scientific publications, Roquefort
Therapeutics has identified the potential to exploit the broad
therapeutic potential of Midkine for a number of clinical
indications of significant unmet need. Roquefort Therapeutics holds
the largest global IP portfolio on Midkine. The Midkine blocking
drug development markets have significant global market potential
(in the multi-billion dollars). Roquefort Therapeutics's
pre-clinical programme is currently underway with an initial focus
on cancer treatment aiming to improve immunotherapy responses.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFLFIDSLIALIF
(END) Dow Jones Newswires
April 20, 2022 02:11 ET (06:11 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Apr 2024 to May 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2023 to May 2024